Next generation targeted protein therapeutics







                                                                    Products



Product pipeline




Product Development Pipeline

Candidate/ Target Lead Discovery Pharmacology Preclinical Clinical Notes
IGN001
Her2
JV funded*
IGN002
CD20
IND filling projected H2 '14 JV funded
IGN003
Multiple Myeloma
JV funded
IGN004
Melanoma/Solid tumors
       
IGN005
AML
       
IGN006
Solid tumors
       

*Funded by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC.

IGN002:


Our lead candidate, IGN002, comprises an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system. CD20 is expressed on Non-Hodgkin lymphoma and other B cell driven hematologic malignancies. We have generated substantial preclinical data with IGN002, including data demonstrating that the targeting ability of IGN002 results in up to 100-fold higher than non-targeted IFN. Further, IGN002 also shows remarkable efficacy in rituximab resistant tumor models. These preclinical data demonstrate that IGN002 effectively targets and acts locally CD20- positive tumors. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC.

IGN001:

Our second candidate, IGN001, comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system. Her2 is expressed on breast cancer and other malignancies. We are in early stages of generating preclinical data with IGN001. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC.

IGN003:

Our IGN003 candidate comprises an monoclonal antibody directed towards a well validated Multiple Myeloma target attached to IFN through stable peptide linker system. We are in early stages of generating preclinical data with IGN003. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC.

IGN004:

Our candidate, IGN004, comprises an monoclonal antibody against a novel target attached to IFN through stable peptide linker system. This target is expressed on multiple solid tumors and melanomas. We are in early stages of generating preclinical data with IGN004.

IGN005:

Our IGN005 candidate comprises an monoclonal antibody directed towards a well validated AML target attached to IFN through stable peptide linker system. This target is expressed on AML and other leukemias. We are in early stages of generating preclinical data with IGN005.

IGN006:

Our candidate, IGN006, comprises an monoclonal antibody against a target attached to IFN through stable peptide linker system. This target is expressed on multiple solid tumors. We are in early stages of generating preclinical data with IGN006.